Effect of royal jelly in athletes

The effect of royal jelly supplement on athlete performance and gene expressions in endurance-trained men: A double-blind, cross-over, clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231209060310N1

Enrollment

Registered

2023-12-21

Start date

2024-02-20

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sports Nutrition.

Interventions

Intervention 1: Intervention group: Participants will take 500 mg of royal jelly tablets twice daily after breakfast and dinner for 2 weeks. The royal jelly tablets will be prepared by the School of P

Eligibility

Sex/Gender

Male

Age

18 Years to 44 Years

Inclusion criteria

Inclusion criteria: Having regular endurance activities at least 3 times per week in the last 6 months Providing written informed consent

Exclusion criteria

Exclusion criteria: Use of antioxidant supplements (for example, vitamin E, vitamin C, ß-carotene, and selenium), royal jelly, or anti-inflammatory drugs in the last three months History of any acute or chronic respiratory diseases, heart diseases, diabetes mellitus, and metabolic disorders Use of any dietary supplements in the last three months Following specific dietary programs Having musculoskeletal diseases or injuries History of any injuries during training or exercise Allergy to bee products and royal jelly

Design outcomes

Primary

Measure	Time frame
Serum Malondialdehyde. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Colorimetric method.;Serum total antioxidant status. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Colorimetric method.;Serum total oxidative status. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Colorimetric method.;Aerobic Capacity. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Bruce test.;Nrf2 gene. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: PCR.;PGC1-a gene. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: PCR.	—

Measure

Time frame

Serum Malondialdehyde. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Colorimetric method.;Serum total antioxidant status. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Colorimetric method.;Serum total oxidative status. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Colorimetric method.;Aerobic Capacity. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Bruce test.;Nrf2 gene. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: PCR.;PGC1-a gene. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: PCR.

—

Secondary

Measure	Time frame
Systolic blood pressure. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Sphygmomanometer.;Diastolic blood pressure. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Sphygmomanometer.;Post-exercise blood pressure. Timepoint: Day 1, 14, 28, and 42 of the study. Method of measurement: Sphygmomanometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Yahya Pasdar

Kermanshah University of Medical Sciences

yahya.pasdar@kums.ac.ir+98 83 3710 2001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026